Profound Medical Corp

Profound Medical Corp

7.34
USD
-0.08
(-1.08%)
-0.93EPS
212.44MMarket Cap
Mar 11Next Earn

Total Valuation

USD

As of September 30, 2026, Profound Medical Corp. carries a market capitalization of 212.44M, placing it among publicly traded companies globally. Its enterprise value stands at 186.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap212.44M
Enterprise Value186.45M

Important Dates

Profound Medical Corp.'s next confirmed earnings release is scheduled for March 11, 2027.

Earnings Date3/11/2027

Share Statistics

As of September 30, 2026, Profound Medical Corp. has 36.63M shares outstanding.

Shares Outstanding36.63M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 8.59, and the price-to-book ratio stands at 5.00.

PS Ratio8.59
PB Ratio5.00
P/TBV Ratio5.01
P/FCF Ratio-6.44
P/OCF Ratio-6.44

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 7.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 186.45M versus a market cap of 212.44M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.89

Financial Position

As of September 30, 2026, Profound Medical Corp. maintains a current ratio of 4.54, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Current Ratio4.54
Quick Ratio3.67
Debt / Equity17.31
Debt / EBITDA-0.22

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Profound Medical Corp. posted a negative return on equity (ROE) of -87.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.68, reflecting losses generated across the asset base. The company generates approximately 145,845.68 in revenue per employee across its workforce of 162.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.66 indicates how many times Profound Medical Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-87.04
Return on Assets (ROA)-64.68
Revenue Per Employee145,845.68
Employee Count162.00
Inventory Turnover0.66

Taxes

USD

Over the twelve months ended September 30, 2026, Profound Medical Corp. recorded 102,000.00 in income tax expense. The company reported a pretax loss of -32.39M and -32.49M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax102,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Profound Medical Corp.'s stock has gained approximately 7.15% over the past 52 weeks. The 50-day moving average sits at 6.32, while the 200-day moving average is 6.64.

52-Week Price Change7.15%
50-Day Moving Average6.32
200-Day Moving Average6.64

Income Statement

USD

Over the twelve months ended September 30, 2026, Profound Medical Corp. generated 23.63M in revenue and converted that into -32.49M in net income, yielding earnings per share of -0.93. EBITDA reached -33.80M, while operating income came in at -34.28M.

Revenue23.63M
Gross Profit17.45M
Operating Income-34.28M
Pretax Income-32.39M
Net Income-32.49M
EBITDA-33.80M
EBIT-34.28M
Earnings Per Share (EPS)-0.93

Balance Sheet

USD

As of September 30, 2026, Profound Medical Corp. holds 33.34M in cash and equivalents against 7.36M in total debt, resulting in a net debt position of -28.83M. Total book value stands at 42.51M, with working capital of 42.77M providing operational flexibility.

Cash & Cash Equivalents33.34M
Total Debt7.36M
Net Debt-28.83M
Equity (Book Value)42.51M
Book Value Per Share1.16
Working Capital42.77M

Cash Flow

USD

Profound Medical Corp. produced -31.49M in operating cash flow over the twelve months ended September 30, 2026.

Operating Cash Flow-31.49M
Free Cash Flow-31.49M
FCF Per Share-0.90

Margins

Over the twelve months ended September 30, 2026, Profound Medical Corp. posted a gross margin of 73.86, reflecting its pricing power and cost economics. The operating margin of -145.08 and net profit margin of -137.51 provide insight into operational efficiency.

Gross Margin73.86
Operating Margin-145.08
Pretax Margin-137.08
Profit Margin-137.51
EBITDA Margin-143.06

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -15.52: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.52, meaning Profound Medical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-19.52
FCF Yield-15.52

Stock Splits

Profound Medical Corp.'s most recent stock split took place on October 16, 2019 with a 10:1 split ratio.

Last Split Date10/16/2019
Split Ratio10:1

Scores

As of September 30, 2026, Profound Medical Corp. has an Altman Z-Score of -0.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.04